Cathy A Swindlehurst
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2016First federal award
$4.0MFederal grants as PI8 awards
0Patents grantedNone matched
19Papers182 citations
Federal awards and patents by year
AwardsPatents
8 awards · $4.0M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Aug 24, 2026 | NIH | SBIR Phase I Novel small molecule for the prevention and treatment of DMD cardiomyopathy | $356K | NOVOMEDIX LLC |
| Sep 22, 2025 | NIH | SBIR Phase I Arthrofibrosis control using small molecule inhibitors of interleukin-11 | $314K | NOVOMEDIX LLC |
| Sep 18, 2024 | NIH | SBIR Phase I Novel oral small molecules for progressive pulmonary fibrosis | $307K | NOVOMEDIX LLC |
| Apr 10, 2023 | NIH | SBIR Phase II Novel small molecules for protection against doxorubicin cardiotoxicity in TNBC | $931K | NOVOMEDIX LLC |
| May 4, 2022 | NIH | SBIR Phase II Novel small molecules for protection against doxorubicin cardiotoxicity in TNBC | $1.1M | NOVOMEDIX LLC |
| Aug 31, 2021 | NIH | SBIR Phase I Novel Therapy for Protection against Diabetes and its Complications in Ischemic Heart Disease | $375K | NOVOMEDIX LLC |
| Sep 18, 2019 | NIH | SBIR Phase I Novel small molecules for protection against doxorubicin cardiotoxicity in TNBC | $375K | NOVOMEDIX LLC |
| Mar 12, 2016 | NIH | SBIR Phase I Novel antifibrotic small molecules for the treatment of heart failure | $300K | NOVOMEDIX LLC |
1 patents as inventor
- US NOVOMEDIX LLC—
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#389
Awards as PI#190
Patents#273
Companies
- NOVOMEDIX LLCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.